1. Indications:

Crizona (Crizotinib) 250 mg is indicated for the treatment of:

• Metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements.
• Advanced or metastatic ALK-positive anaplastic large cell lymphoma (ALCL).
• Metastatic ROS1-positive NSCLC.

2. Pharmacology:

Crizona (Crizotinib) 250 mg exerts its pharmacological effects by inhibiting the activity of multiple receptor tyrosine kinases, including ALK, ROS1, and MET. By blocking these signaling pathways, Crizona impedes cancer cell proliferation, migration, and survival, ultimately leading to tumor regression.

3. Dosage and Administration:

The recommended dosage of Crizona (Crizotinib) 250 mg may vary depending on the type of cancer being treated and individual patient characteristics. Typically, the prescribed dose is 250 mg taken orally twice daily, with or without food. Treatment should continue until disease progression or unacceptable toxicity occurs.

4. Interaction:

Crizona (Crizotinib) 250 mg may interact with other medications, including:

• Strong CYP3A inhibitors or inducers: Co-administration with drugs that affect CYP3A metabolism may alter the plasma concentration of Crizona.
• Proton pump inhibitors (PPIs) and H2-receptor antagonists: Concurrent use of these agents may reduce the absorption of Crizona, potentially decreasing its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to minimize the risk of potential interactions.

5. Side Effects:

Common side effects associated with Crizona (Crizotinib) 250 mg may include:

• Nausea
• Diarrhea
• Fatigue
• Edema
• Vision disorders
• Elevated liver enzymes

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Crizona (Crizotinib) 250 mg, patients should be aware of the following precautions:

• Crizona may cause interstitial lung disease (ILD) or pneumonitis, which can be fatal. Patients should be monitored for respiratory symptoms and undergo regular imaging studies during treatment.
• Hepatotoxicity, including liver function abnormalities, has been reported with Crizona. Liver function tests should be performed before starting treatment and periodically thereafter.
• Crizona may prolong the QT interval, increasing the risk of arrhythmias. Electrocardiograms (ECGs) should be monitored regularly, especially in patients with pre-existing cardiac conditions.

7. Overdose Effects:

In case of overdose with Crizona (Crizotinib) 250 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Crizona overdose, and patients should seek immediate medical attention if overdose is suspected.